Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.6
4.9
Journals
Biosensors
Special Issues
Biosensing Technologies in Medical Diagnosis
share announcement

Biosensing Technologies in Medical Diagnosis

A special issue of Biosensors (ISSN 2079-6374). This special issue belongs to the section "Biosensor and Bioelectronic Devices".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1025

Special Issue Editors

Prof. Dr. Niancai Peng

E-Mail Website
Guest Editor
State Key Laboratory for Manufacturing Systems Engineering, Xi'an, China
Interests: biomedical testing technology and instrumentation
Dr. Fei Hu

E-Mail Website
Guest Editor
School of Instrument Science and Technology, Xi’an Jiaotong University, Xi’an 710054, China
Interests: biosensor; nucleic acid; diagnostics

Special Issue Information

Dear Colleagues,

As an effective means of obtaining biological information, biosensing is a pioneering and core technology in medical diagnostics. Innovation and application progress in this technology are critical for the development of new diagnostic methods and instruments. Biosensing-based analytical methods, including early and rapid diagnosis, bedside supervision, and in vivo monitoring, provide important guidance for immediate and precision medical care.

This Special Issue focuses on the innovative advances and applications of biosensing technologies in medical diagnostics. The Issue invites manuscripts (research papers, perspectives, and review articles) related to biosensing applications including, but not limited to, bioassay, bioseparation, point-of-care tests, gene engineering, cell analysis, drug screening, tissue engineering, regenerative medicine, personalized healthcare, etc. Articles regarding the integration of advanced diagnostic techniques and testing devices are also encouraged to be submitted. We look forward to receiving your contributions and sharing the latest advances in the application of biosensing technologies in medical diagnosis with our readers.

Prof. Dr. Niancai Peng
Dr. Fei Hu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biosensors is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diagnostics
  • biodetection
  • biosensors
  • bioseparation
  • biomaterial
  • genomics
  • nucleic acid detection
  • immunoassay
  • wearable medical testing
  • microfluidics and its application to medical testing
  • cell analysis
  • point-of-care testing
  • drug screening
  • tissue engineering
  • regenerative medicine
  • personalized healthcare

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 3399 KiB  
Article
Characterization of Receptor Binding Affinity for Vascular Endothelial Growth Factor with Interferometric Imaging Sensor
by Nese Lortlar Ünlü, Monireh Bakhshpour-Yucel, Elisa Chiodi, Sinem Diken-Gür, Sinan Emre and M. Selim Ünlü
Biosensors 2024, 14(7), 315; https://doi.org/10.3390/bios14070315 - 24 Jun 2024
Viewed by 326
Abstract
Wet Age-related macular degeneration (AMD) is the leading cause of vision loss in industrialized nations, often resulting in blindness. Biologics, therapeutic agents derived from biological sources, have been effective in AMD, albeit at a high cost. Due to the high cost of AMD [...] Read more.
Wet Age-related macular degeneration (AMD) is the leading cause of vision loss in industrialized nations, often resulting in blindness. Biologics, therapeutic agents derived from biological sources, have been effective in AMD, albeit at a high cost. Due to the high cost of AMD treatment, it is critical to determine the binding affinity of biologics to ensure their efficacy and make quantitative comparisons between different drugs. This study evaluates the in vitro VEGF binding affinity of two drugs used for treating wet AMD, monoclonal antibody-based bevacizumab and fusion protein-based aflibercept, performing quantitative binding measurements on an Interferometric Reflectance Imaging Sensor (IRIS) system. Both biologics can inhibit Vascular Endothelial Growth Factor (VEGF). For comparison, the therapeutic molecules were immobilized on to the same support in a microarray format, and their real-time binding interactions with recombinant human VEGF (rhVEGF) were measured using an IRIS. The results indicated that aflibercept exhibited a higher binding affinity to VEGF than bevacizumab, consistent with previous studies using ELISA and SPR. The IRIS system’s innovative and cost-effective features, such as silicon-based semiconductor chips for enhanced signal detection and multiplexed analysis capability, offer new prospects in sensor technologies. These attributes make IRISs a promising tool for future applications in the development of therapeutic agents, specifically biologics. Full article
(This article belongs to the Special Issue Biosensing Technologies in Medical Diagnosis)
►▼ Show Figures

Figure 1

16 pages, 6549 KiB  
Article
Integrated High-Throughput Centrifugal Microfluidic Chip Device for Pathogen Detection On-Site
by Shuyu Lu, Yuanzhan Yang, Siqi Cui, Anyi Li, Cheng Qian and Xiaoqiong Li
Biosensors 2024, 14(6), 313; https://0-doi-org.brum.beds.ac.uk/10.3390/bios14060313 - 19 Jun 2024
Viewed by 364
Abstract
An integrated and high-throughput device for pathogen detection is crucial in point-of-care testing (POCT), especially for early diagnosis of infectious diseases and preventing the spread of infection. We developed an on-site testing platform that utilizes a centrifugal microfluidic chip and automated device to [...] Read more.
An integrated and high-throughput device for pathogen detection is crucial in point-of-care testing (POCT), especially for early diagnosis of infectious diseases and preventing the spread of infection. We developed an on-site testing platform that utilizes a centrifugal microfluidic chip and automated device to achieve high-throughput detection. The low-power (<32 W), portable (220 mm × 220 mm × 170 mm, 4 kg) device can complete bacterial lysis, nucleic acid extraction and purification, loop-mediated isothermal amplification (LAMP) reaction, and real-time fluorescence detection. Magnetic beads for nucleic acid adsorption can be mixed by applying electromagnetic fields and centrifugal forces, and the efficiency of nucleic acid extraction is improved by 60% compared to the no-mixing group. The automated nucleic acid extraction process achieves equivalent nucleic acid extraction efficiency in only 40% of the time consumed using the kit protocol. By designing the valve system and disc layout, the maximum speed required for the centrifugal microfluidic chip is reduced to 1500 rpm, greatly reducing the equipment power consumption and size. In detecting E. coli, our platform achieves a limit of detection (LOD) of 102 CFU/mL in 60 min. In summary, our active centrifugal microfluidic platform provides a solution for the integration of complex biological assays on turntables, with great potential in the application of point-of-care diagnosis. Full article
(This article belongs to the Special Issue Biosensing Technologies in Medical Diagnosis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop